554 related articles for article (PubMed ID: 31643072)
1. Vaccination for quality of life: herpes-zoster vaccines.
Lang PO; Aspinall R
Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
[TBL] [Abstract][Full Text] [Related]
2. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
3. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
5. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
6. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
Giannelos N; Ng C; Curran D
Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
[TBL] [Abstract][Full Text] [Related]
8. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination against herpes zoster].
Larsen CS; Helleberg M
Ugeskr Laeger; 2021 Nov; 183(47):. PubMed ID: 34851258
[TBL] [Abstract][Full Text] [Related]
10. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
12. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
[TBL] [Abstract][Full Text] [Related]
13. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
14. Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
[TBL] [Abstract][Full Text] [Related]
15. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
17. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
18. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
